Cargando…
Kwiatkowski JL, Hamdy M, El-Beshlawy A, et al. Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. Blood Adv. 2022;6(4):1243-1254.
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
The American Society of Hematology
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333737/ https://www.ncbi.nlm.nih.gov/pubmed/37368454 http://dx.doi.org/10.1182/bloodadvances.2023009896 |
| _version_ | 1785070729693233152 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10333737 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | The American Society of Hematology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-103337372023-07-12 Kwiatkowski JL, Hamdy M, El-Beshlawy A, et al. Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. Blood Adv. 2022;6(4):1243-1254. Blood Adv Erratum The American Society of Hematology 2023-06-27 /pmc/articles/PMC10333737/ /pubmed/37368454 http://dx.doi.org/10.1182/bloodadvances.2023009896 Text en © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Erratum Kwiatkowski JL, Hamdy M, El-Beshlawy A, et al. Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. Blood Adv. 2022;6(4):1243-1254. |
| title | Kwiatkowski JL, Hamdy M, El-Beshlawy A, et al. Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. Blood Adv. 2022;6(4):1243-1254. |
| title_full | Kwiatkowski JL, Hamdy M, El-Beshlawy A, et al. Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. Blood Adv. 2022;6(4):1243-1254. |
| title_fullStr | Kwiatkowski JL, Hamdy M, El-Beshlawy A, et al. Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. Blood Adv. 2022;6(4):1243-1254. |
| title_full_unstemmed | Kwiatkowski JL, Hamdy M, El-Beshlawy A, et al. Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. Blood Adv. 2022;6(4):1243-1254. |
| title_short | Kwiatkowski JL, Hamdy M, El-Beshlawy A, et al. Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. Blood Adv. 2022;6(4):1243-1254. |
| title_sort | kwiatkowski jl, hamdy m, el-beshlawy a, et al. deferiprone vs deferoxamine for transfusional iron overload in scd and other anemias: a randomized, open-label noninferiority study. blood adv. 2022;6(4):1243-1254. |
| topic | Erratum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333737/ https://www.ncbi.nlm.nih.gov/pubmed/37368454 http://dx.doi.org/10.1182/bloodadvances.2023009896 |